NMPA Accepts Marketing Application for VASCEPA® (icosapent ethyl) Cardiovascular Risk Reduction (CVRR) Indication

We are a fully integrated biopharmaceutical company dedicated to bringing promising therapeutics to patients in underserved therapeutic areas in China.

We started our business in 2001 collaborating with global pharmaceutical MNCs to distribute their products in China. Through years of collaboration with MNCs, we have developed full value chain capabilities that laid the foundation for our evolution into an integrated biopharmaceutical company.

With deep knowledge of the China market and recognition by MNC partners of our value chain capabilities, we have successfully acquired full product rights for a portfolio of de-risked drug assets to address China’s unmet medical needs and have evolved into a marketing authorization holder responsible for drug quality for their entire lifecycle.

Learn more

We have established a diversified product portfolio comprising six core products. 

Learn more

We are one of the few domestics pharmaceutical companies in China that possess advanced quality management, manufacturing and international supply chain management capabilities.

Learn more
Commercial Operation

We have a well-established sales and marketing system with a proven track record. Our professional marketing and operational team and efficient data-driven operations enhance the accessibility of critical medical products and enable more patients to benefit from both our branded-products and innovative drugs.

Leveraging our deep market insights, we have been able to successfully identify and acquire or in-license high quality products that address unmet medical needs in China. We are committed to building an integrated drug research and development platform which focuses primarily on three core therapeutic areas: anti-infective, CVD and respiratory system.

Learn more
Unit 122-129, Building A3, No. 700, Wanrong Road, Shanghai,China



Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038